|
|
|
Volumn 26, Issue 4 SUPPL. 12, 1999, Pages 89-95
|
|
Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CISPLATIN;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ANEMIA;
ARTICLE;
ASTHENIA;
BACKACHE;
BREAST CANCER;
BREAST METASTASIS;
CANCER COMBINATION CHEMOTHERAPY;
CHEMOSENSITIVITY;
CLINICAL TRIAL;
DNA DAMAGE;
DRUG EFFECT;
DRUG EFFICACY;
DYSPNEA;
HUMAN;
HYPERGLYCEMIA;
INFECTION;
MITOGENICITY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
THROMBOCYTOPENIA;
TUMOR XENOGRAFT;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CISPLATIN;
FEMALE;
HUMANS;
NEOPLASM METASTASIS;
RECEPTOR, ERBB-2;
|
|
EID: 0032825577
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (173)
|
|
References (16)
|
